(3-(5-methyl-1H-imidazol-1-yl)propyl)-2-cyano-3-(naphthalen-2-yl)guanidine | 1073243-10-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: (3-(5-methyl-1H-imidazol-1-yl)propyl)-2-cyano-3-(naphthalen-2-yl)guanidine
• 英文别名: 1-Cyano-2-[3-(5-methylimidazol-1-yl)propyl]-3-naphthalen-2-ylguanidine
• CAS: 1073243-10-3
• 化学式: C₁₉H₂₀N₆
• 分子量: 332.408
• InChiKey: LFUDVSMHWTZKGD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  25
• 可旋转键数：
  7
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.21
• 拓扑面积：
  78
• 氢给体数：
  2
• 氢受体数：
  3

文献信息

• NOVEL INHIBITORS OF GLUTAMINYL CYCLASE
  申请人：Buchholz Mirko

  公开号：US20080267912A1

  公开（公告）日：2008-10-30

  Compounds of formula (I), combinations and uses thereof for disease therapy, or a pharmaceutically acceptable salt, solvate or polymorph thereof, including all tautomers and stereoisomers thereof wherein: A represents and B, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 and Z are as defined throughout the description and the claims.

  化合物的公式（I），其组合物及用于疾病治疗的用途，或其药用盐、溶剂化合物或多晶体，包括其所有互变异构体和立体异构体，其中：A代表和B，R1，R2，R3，R4，R5，R6和Z如描述和索赔中定义的那样。
• TREATING PATHOLOGICAL CONDITIONS BY DIRECT AND INDIRECT TARGETING OF SIRPA - CD47 INTERACTION
  申请人：Stichting Het Nederlands Kanker Instituut- Antoni van Leeuwenhoek Ziekenhuis

  公开号：EP3747438A1

  公开（公告）日：2020-12-09

  The present invention relates to active agents or compounds as well as pharmaceutical compositions comprising said compounds, which are capable of reducing or inhibiting or blocking the enzymatic activity of the glutaminyl-peptide cyclotransferase (QPCT) protein, the glutaminyl-peptide cyclotransferase-like protein (QPCTL) protein, or combinations thereof or are capable of reducing or inhibiting the expression of QPCT gene, the QPCTL gene, or combinations thereof. Also provided are methods for screening or selecting for said compounds. The present invention further relates to a pharmaceutical composition comprising a first active agent for use in a method of treating a condition in a subject that would benefit from reducing the signaling or the binding between SIRPa and CD47 in the subject (e.g. cancer), wherein the method of treating comprises reducing expression or enzymatic activity of QPCTL, QPCT, or combinations thereof in the cell with CD47 on the surface. The compounds and pharmaceutical compositions of the invention may be particularly useful for treating a subject suffering from a disease or condition involving the CD47-SIRPa signaling axis such including e.g., various cancer types, atherosclerosis, fibrotic diseases, and infectious diseases.

  本发明涉及活性剂或化合物以及包含所述化合物的药物组合物，它们能够降低或抑制或阻断谷氨酰胺酰肽环转酶（QPCT）蛋白、谷氨酰胺酰肽环转酶样蛋白（QPCTL）蛋白或其组合的酶活性，或者能够降低或抑制QPCT基因、QPCTL基因或其组合的表达。还提供了筛选或选择所述化合物的方法。本发明进一步涉及一种药物组合物，该药物组合物包含第一活性剂，用于治疗受试者（如癌症）中可从减少SIRPa和CD47之间的信号转导或结合中获益的病症的方法，其中治疗方法包括减少表面有CD47的细胞中QPCTL、QPCT或其组合的表达或酶活性。本发明的化合物和药物组合物可能特别适用于治疗患有涉及 CD47-SIRPa 信号轴的疾病或病症的受试者，例如包括各种癌症类型、动脉粥样硬化、纤维化疾病和传染性疾病。
• CYANO-GUANIDINE DERIVATIVES AS GLUTAMINYL CYCLASE INHIBITORS
  申请人：Probiodrug AG

  公开号：EP2160380A1

  公开（公告）日：2010-03-10
• US8227498B2
  申请人：——

  公开号：US8227498B2

  公开（公告）日：2012-07-24
• [EN] CYANO-GUANIDINE DERIVATIVES AS GLUTAMINYL CYCLASE INHIBITORS<br/>[FR] DÉRIVÉS DE CYANO-GUANIDINE UTILISÉS COMME INHIBITEURS DE LA GLUTAMINYL CYCLASE
  申请人：PROBIODRUG AG

  公开号：WO2008128983A1

  公开（公告）日：2008-10-30

  [EN] The present invention relates to compounds of formula (I), combinations and uses thereof for disease therapy, or a pharmaceutically acceptable salt, solvate or polymorph thereof, including all tautomers and stereoisomers thereof wherein: A represents formula (A) or formula (B) and B, R¹, R², R³, R⁴, R⁵, R⁶ and Z are as defined throughout the description and the claims.
  [FR] La présente invention concerne des composés de formule (I), des combinaisons et utilisations desdits composés pour le traitement de maladies, ou un sel pharmaceutiquement acceptable, solvat ou polymorphe desdits composés, y compris tous leurs tautomères et stéréoisomères. Dans ladite formule, A représente la formule (A) ou la formule (B) et B, R¹, R², R³, R⁴, R⁵, R⁶ et Z sont tels que définis dans l'ensemble de la description et des revendications.